Metabolomics Used to Discover Biomarkers for Periodontal Disease
RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 29, 2009 - Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying biomarkers for periodontitis and gingivitis. Co-authored by scientists at Colgate-Palmolive, The Forsyth Institute and Metabolon, the paper, “Acceleration of Purine Degradation Pathway by Periodontal Disease”, appears in the Journal of Dental Research (Volume 88, No. 9, 851-855 (September 2009)).
Using Metabolon’s biochemical profiling technology, mechanistically-linked biomarkers were discovered and validated from the crevicular fluid of patients suffering from periodontitis and gingivitis. Several hundred biochemicals were identified in a few microliters of the crevicular fluid found between the tooth and gums. The biomarkers suggest that the diseases are mediated by enhanced purine degradation, a biochemical pathway associated with reactive oxygen species production and cellular inflammation.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
